Search PubMed⌕ Search

Biomedical subjects

B Kimmig

Publications and source records attributed to B Kimmig.

At least 73 records · Page 4Linked to original sources
PubMed1986

Iodine-131-labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3.

The kinetics, dosimetry, and response of iodine-131 alpha-amino-(4-hydroxybenzylidene)-diphosphonate ([131I]BDP3) treatment were investigated with patients who had pain symptoms from bone metastases of various primary carcinoma. The blood clearance of [131I]BDP3 was rapid. More than 90% disappeared from the blood pool at 2 hr after injection. The excretion of the activity occurred solely through the kidneys and mean total-body retention at 48 hr was 48.6%. The urinary activity showed a metabolite which must be formed by an in vivo cleavage reaction of a phosphorus-carbon bond. The uptake of in vivo cleaved [131I]iodide in the unblocked thyroid was approximately 0.5%. The effective half-life of [131I]BDP3 in metastatic bone (median 182 hr; range 177-205 hr) proved to be longer than in unaffected areas (145 hr; 140-165 hr). Palliative therapies were performed with 18 patients. They received doses ranging between 6 and 48 mCi [131I]BDP3. The response was 44% complete pain relief, 6% substantial pain relief, 22% minimal improvement, and 28% no change. The duration of response ranged between 1 and 8 wk.

Benzylidene Compounds↗
PubMed1985

[Diagnosis and therapy control of neuroblastoma using meta-iodo- benzylguanidine].

Meta-iodine-benzylguanidine (MIBG) scanning provides, for the first time, specific radiological means for diagnosis, treatment follow-up and post-treatment care of patients with neuroblastoma. Of 10 such patients studied by MIBG scanning, 7 had histologically confirmed neuroblastoma. In 6 of them there was markedly increased activity in the primary tumor, in 3 metastases were demonstrated. In at least one patient the intensity of increased activity suggested the possibility of selective therapeutic administration.

3-Iodobenzylguanidine↗
PubMed1985

[Scintigraphic imaging of benign and malignant tumors of the sympathetic nervous system with meta-iodobenzylguanidine].

The authors report on their experiences with metaiodine-benzylguanidine (MIBG) scintiscanning in a total of 36 patients. 7 of these patients had a benign pheochromocytoma, 4 a malignant one; neuroblastoma was seen in 10 patients. Scintiscan diagnosis was supplemented by measurements of irradiation exposure and attainable tumour dose. It was also shown that it is possible to mark neuroblastoma cells in cultures. The results of these studies are discussed and compared with those of other working groups. If the physiological pattern of distribution is taken into consideration, and if the proper imaging technique is adopted, MIBG scintiscan is a sensitive and highly specific method in diagnosing pheochromocytomas and neuroblastomas.

3-Iodobenzylguanidine↗
PubMed1985

[Computed tomography in follow-up of differentiated thyroid carcinoma].

The importance of computed tomography in follow-up aftercare and therapy planning in differentiated carcinoma of the thyroid is examined on the basis of the authors' experiences in a group of about 600 patients. The individual indication ranges are discussed and demonstrated by means of examples.

Adenocarcinoma↗
PubMed1985

[Use of electrons above 20 MeV for reduction of radiation exposure].

After many years of clinical application of a 42 MeV betatron, the following indications were found for deep therapy with electrons above 20 MeV: tumors situated in the brain, mediastinum, kidney, liver, bladder, rectum, as well as peripheral tumors situated in different body regions. For eight different cases, the total body exposure and the radiation exposure of some risk organs was calculated for an irradiation with electrons alone, a combination of electrons and photons, an irradiation with 42 MeV X-rays and with Co-60 gamma rays alone. All these calculations were based on a most favorable irradiation technique. The results showed that electrons up to 40 MeV can spare more than 30% of the total body dose; a combination of electrons and photons allows a reduction of the total dose of about 15% as against that of photons alone, which makes possible a better conservation of skin. This total dose reduction corresponds to that achieved by the substitution of ultrahard X-radiation for Co-60 gamma radiation in deep therapy. The radiation exposure of risk organs can often be reduced by the use of electrons, too. Thus electron deep therapy shows to be justified for the mentioned tumor cases. This is also confirmed by clinical experience.

Beta Particles↗
PubMed1984

[Long-term observation of 15 patients with differentiated thyroid cancer and elevated plasma thyroglobulin levels of unclear origin].

The follow-up of 15 patients with differentiated cancer of the thyroid was analysed retrospectively. All patients had persistent or developed elevated thyroglobulin (Tg) plasma levels (greater than 10 ng/ml) after total thyroidectomy and 131 I therapy. There was no evidence of thyroid remnants or metastases in the 131 I whole body scan, bone scan, chest X-ray or clinical investigation. Nine of 15 patients developed local or distant metastases during a follow-up period of 3-39 months (mean = 18 months). Only one of seven recurrences tested were 131 I positive, Tg values of 9 from 12 patients showed no correlation to the Thyroid-stimulating hormone (TSH) level. It is concluded that: (1) this group of patients is at high risk of developing a recurrence (2) new methods have to be developed for the localization of 131 I negative but Tg positive metastases.

Adenocarcinoma↗
PubMed1984

Dual isotope scintigraphy in stroke patients.

Platelet scintigraphy is a useful technique to detect atherosclerotic lesions of the neck vessels in stroke patients. The habitual one isotope technique causes false positive and false negative results due to circulating platelet-bound activity. To eliminate these confusing results we performed a dual isotope technique on 20 stroke patients. The new method consists of simultaneous injections of 111-Indium labelled blood platelets and 99mTc labelled red cells, and achieves a calculation of the ratio 111-In/99mTc. Thus the subtraction of the red cell blood flow image can render a pure thrombus formation visible. The habitual visually evaluated one isotope scintigraphy showed positive scans in 11 out of 20 patients, whereas under dual isotope scintigraphy 3 patients showed no 111-Indium excess after subtraction of the red cell image; they can thus be qualified as false positive. In the case of another patient with a visually negative image a thrombus formation could be observed after the subtraction procedure. It seems, that the dual isotope technique in platelet scintigraphy is a valuable refinement on the way to verifiable results.

Blood Platelets↗
PubMed1984

[Computed tomography and scintigraphy in malignant pheochromocytoma].

Two patients with malignant metastasising phaeochromocytomas are described. Special attention is paid to the findings on computed tomography and scintigraphy with meta-I-benzylguanidine. The scintigraphic findings are not uniform. A review of the literature has shown that the sensitivity of scintigraphy is less for malignant phaeochromocytomas than it is for benign tumours.

3-Iodobenzylguanidine↗
PubMed1984

[Lithium as an adjuvant in the radioiodine therapy of thyroid cancer].

14 patients were, after surgery for thyroid cancer, given radioiodine to ablate residual thyroid tissue, and, in addition, lithium carbonate. In 8 patients increasing serum lithium levels between 0.3 and 0.9 mmol/l and in 6 patients a constant level higher than 0.9 mmol/l were achieved. The radioiodine kinetics were compared with a control group of 16 patients without lithium therapy. Neither in a low nor in a high dosage the lithium medication could increase 131I uptake or prolong its effective half-life in the residual thyroid. Thus with lithium an increase of tumor dose could not be achieved. We suggest that in our patients the effect of lithium on thyroid metabolism was compensated by the enormous TSH-stimulation after thyroidectomy.

Adult↗
PubMed1984

[Radioiodine therapy of differentiated thyroid cancer. 10-year results of a standardized therapy in 269 patients].

Between 1969 and 1977, 269 patients submitted to thyroidectomy were treated exclusively with radioiodine according to a standardized irradiation scheme. The patients were observed during thirteen years. 195 patients were free of metastases at the time of the first therapy, whereas 74 patients had lymph node metastases or remote metastases. The survival rates of the total group were 89% (five years) and 76% (10 years), respectively. Patients with regional lymph node metastases had a ten-year survival rate of 74%. The fourty patients suffering from remote metastases had a five-year survival rate of 75% and a ten-year survival rate of 40%. Patients who were in stage T3 at the moment of diagnosis had a survival probability of 74% for five years and of 59% for eight years. None of these patients presented with remote metastases during the follow-up period. Taking into consideration these results and the small rate of complications, we are of the opinion that a routine combination therapy with external post-irradiation is not necessary.

Adenocarcinoma↗
PubMed1984

[Ultrasound in the diagnosis of malignant lymphomas].

Optimal treatment of a malignant lymphoma demands accurate staging at the time of first diagnosis. In addition, it is mandatory to perform reproducible therapy control and closely meshed follow-up care. In this connection, sonography occupies an unrivalled place as a non-invasive, relatively uncomplicated and economical examination method. The ranking depends in individual cases on the diagnostic importance and informative value of rival methods, such as lymphography and computed tomography.

Hepatomegaly↗
PubMed1984

[Nuclear medicine diagnosis of malignant lymphomas].

Non-invasive and hazard-free methods for diagnosing malignant lymphomas are represented by scintigraphy with gallium 67 and by lymphoscintigraphy, especially of the retroperitoneum. These methods are particularly suitable for closely following up the course of the disease. In this article, radiopharmacology, pharmacokinetics and techniques of examination associated with these methods, are described, and typical findings are demonstrated by means of clinical case examples. Attention is also paid to radiation exposure load. The ranking of these methods within the framework of x-ray diagnostics, is also discussed.

Adult↗
PubMed1984

Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine.

Radioiodinated m-iodobenzylguanidine has been applied mainly for the diagnosis of pheochromocytoma and blastoma. In this paper we show that an ontogenetically related tumor, the neuroblastoma, is also scintigraphically visualized by its high uptake of I-131 MIBG. Because of the kinetic findings and the high uptake of more than 30% of the injected activity, it is likely that the neuroblastoma, by analogy with pheochromocytoma, is susceptible to specific radionuclide therapy.

3-Iodobenzylguanidine↗
PubMed1983

[Diagnostic value of 131I-whole body scintigraphy in the after care of differentiated thyroid cancer].

The value of scintiscanning after treatment and of routine control scanning in differentiated thyroid carcinoma was evaluated in a retrospective study for the diagnosis of metastases and recurrencies. Scintigrams after treatment detected 76% of all metastases at the time of primary treatment. In contrast, only 4 (18%) out of 22 late relapses were positive in the radioiodo-scintigram. Three of these had been diagnosed earlier already on clinical grounds. Thus, routine whole-body scintigrams using 2 mCi 131I for the after-care of differentiated thyroid carcinoma is without relevant benefit for patients, and certainly not if an aggressive treatment concept has been followed from the beginning. Whole-body scintigraphy should be used only in exceptional cases. Follow-up care should be based on regular thyreoglobulin assessment using a sensitive and controlled method.

Aftercare↗
PubMed1983

The clinical use of platelet scintigraphy with 111-In-oxine.

Platelet scintigraphy was performed on 62 patients with cerebral ischaemia. Pathological scintigraphic images were obtained in 29 of the 62 patients. In 79.3% of these 29 patients the scan was abnormal in the vessel clinically affected. Platelet scintigraphy was abnormal in 21 of 34 patients with normal angiogram or only slight atherosclerosis. In patients undergoing antiplatelet therapy, platelet scintigraphy was less often positive than in untreated patients. It is suggested that platelet scintigraphy could be an appropriate technique for detecting small mural thrombi of the carotid artery, which are the source of arterio-arterial emboli, and for controlling the efficiency of antiplatelet therapy.

Adult↗
PubMed1983

[Angio-CT: an improvement in the diagnosis of malignant liver diseases].

Dynamic contrast studies of the liver make it possible to evaluate the vascularity of liver metastases. Up to the present, the examination has only been carried out in single planes, whereas studies of the whole of the liver during one examination have not yet been published. This can be obtained by performing sequential CT (angio-CT), using special software. A clinical study of the value of the procedure has been undertaken on 64 patients with suspected liver metastases. In addition to the plain scans, the examination was repeated during the early phase of a bolus injection and subsequently ten minutes after injection (enhancement). The various structures which can be seen are described and the changes in density patterns have been interpreted according to contrast kinetics derived from nephrographic examinations. The advantages of angio-CT as compared with plain films and with scans after normal contrast infusions are described. The improved sensitivity and specificity obtained by using the three modes of examination, as compared with a single examination, is stressed.

Breast Neoplasms↗